AMG 305
Alternative Names: AMG-305Latest Information Update: 23 Nov 2023
At a glance
- Originator Amgen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Germany, South Korea, Spain, France (IV) (NCT05800964)
- 13 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia and USA (IV) (NCT05800964)
- 14 Apr 2023 Pharmacodynamic and adverse events data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)